Close Menu

NEW YORK – Despite the COVID-19 pandemic, Oncocyte has been making progress in its efforts to ramp up clinical testing and pursue new research opportunities, company executives said this week.

Specifically, the company has been engaged in health economic research to support commercialization of its DetermaRx assay, and has generated new data on the predictive nature of its more recently acquired research-use DetermIO test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.